Novartis: Bronchiolitis Obliterans Syndrome trials
The registry lists 17 Bronchiolitis Obliterans Syndrome studies with Novartis as lead sponsor. 1 are open to participants now and 11 have results posted.
Phase 1 1Phase 2 8Phase 3 6Phase 4 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPRecruitingNCT07354074Phase 2
- Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine PatientsCompletedNCT03867201Phase 3Results posted
- Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell TransplantCompletedNCT03774082Phase 2Results posted
- A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) PatientsCompletedNCT02649218Phase 2Results posted
- Safety and Efficacy Study of SOM230 s.c. in Cluster HeadacheTerminatedNCT02619617Phase 2Results posted
- Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSUCompletedNCT02477332Phase 2Results posted
- Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIACompletedNCT02396212Phase 3Results posted
- A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 StudiesCompletedNCT02334748Phase 3Results posted
- ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of CanakinumabCompletedNCT02296424Phase 3Results posted
- Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.CompletedNCT01844765Phase 2Results posted
- Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic LeukemiaCompletedNCT01313689Phase 3Results posted
- Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to ImatinibCompletedNCT00802841Phase 3Results posted
- Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I MutationCompletedNCT06427811Phase 4
- Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase InhibitorsCompletedNCT04795427Phase 2
- CINC424A2X01B Rollover ProtocolActive, not recruitingNCT02386800Phase 4
- Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection SubjectsTerminatedNCT00964665Phase 1/2
- To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)CompletedNCT00537537Phase 4